

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended): A modified anti-viral peptide comprising
a peptide having been modified to contain a ~~succinimide~~ or maleimide containing group
which is reactive with ~~amino groups, hydroxyl groups, or thiol groups on blood components~~
cysteine 34 of serum albumin to form a stable covalent bonds, said peptide comprising an amino
acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:147, SEQ ID
NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542,
SEQ ID NO:543, SEQ ID NO:544, and SEQ ID NO:545, said sequence exhibiting an anti-viral
activity against human immunodeficiency virus (HIV) wherein said peptide is covalently bonded to
cysteine 34 of serum albumin, wherein the ratio of peptide to serum albumin is 1:1.

Claim 2 (canceled)

Claim 3 (canceled)

Claim 4 (previously presented): The modified peptide of claim 1 wherein said peptide
is DP 107 and comprises the amino acid sequence of SEQ ID NO:2.

Claim 5 (canceled)

Claim 6 (previously presented): The modified peptide of claim 1 wherein said peptide
is selected from the group consisting of SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ
ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, SEQ ID
NO:544, and SEQ ID NO:545.

Claims 7-18 (canceled)

Claim 19 (currently amended): A composition for use in the prevention and/or treatment of acquired immune deficiency syndrome (AIDS) comprising, in a physiologically acceptable medium, a modified peptide including a peptide having been modified to contain a ~~succinimidyl or maleimide containing group which is reactive with amino groups, hydroxyl groups, or thiol groups on blood components~~ cysteine 34 of serum albumin to form a stable covalent bonds, said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, SEQ ID NO:544, and SEQ ID NO:545, said sequence exhibiting an anti-viral activity against human immunodeficiency virus (HIV) wherein said peptide is covalently bonded to cysteine 34 of serum albumin, wherein the ratio of peptide to serum albumin is 1:1.

Claim 20 (canceled)

Claim 21 (previously presented): The composition of claim 20 wherein said peptide is DP 107 comprising the amino acid sequence of SEQ ID NO:2.

Claims 22-30 (canceled)

Claim 31 (previously presented): The composition of claim 19 wherein said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, SEQ ID NO:544, and SEQ ID NO:545.

Claims 32-35 (canceled)

Claim 36 (previously presented): A composition comprising the modified anti-viral peptide of claim 1 in a physiologically acceptable medium.

Claim 37 (canceled)

Claim 38 (previously presented): The composition of claim 36 wherein said modified anti-viral peptide comprises the amino acid sequence of SEQ ID NO:2.

Claim 39 (previously presented): The composition of claim 36 wherein said modified anti-viral peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, SEQ ID NO:544, and SEQ ID NO:545.

Claim 40-55 (canceled)